{"id":984605,"date":"2026-07-24T08:27:02","date_gmt":"2026-07-24T12:27:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026\/"},"modified":"2026-07-24T08:27:02","modified_gmt":"2026-07-24T12:27:02","slug":"immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026\/","title":{"rendered":"Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">\n        <b>SYDNEY, AUSTRALIA, July  24, 2026  (GLOBE NEWSWIRE) &#8212; <\/b><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=G4x3ZuuDD5EpYYsRTWxg9PA-G8UtFtfiQiyhJ5p4Dr__0h71UL_626FnIrlTeatti1-35qK3JiUnnHfKrVcd4vCxtNIHY2d87kEsX4sS3vM=\" rel=\"nofollow\" target=\"_blank\">Immutep Limited<\/a> (ASX: IMM; NASDAQ: IMMP) (\u201cImmutep\u201d or \u201cthe Company\u201d), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announced that an abstract for the investigator-initiated EFTISARC-NEO Phase II trial evaluating its first-in-class MHC Class II agonist, eftilagimod alfa (\u201cefti\u201d), has been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place 23\u201327 October 2026 in Madrid, Spain.<\/p>\n<p align=\"justify\">The abstract reports health-related quality of life (HRQoL) data from EFTISARC-NEO. Details of the accepted abstract and poster are as follows:<\/p>\n<table style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <b>Title<\/b>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Health-related quality of life (HRQoL) during neoadjuvant treatment with eftilagimod alfa, pembrolizumab and radiotherapy in patients with soft tissue sarcoma (STS) \u2013 results from EFTISARC-NEO trial<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <b>Trial<\/b>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">EFTISARC-NEO (investigator-initiated Phase II; NCT06128863)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <b>Session category<\/b>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">ePoster<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <b>First Author<\/b>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Pawel Teterycz, M.D., Maria Sk\u0142odowska-Curie National Research Institute of Oncology (MSCNRIO), Warsaw, Poland<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <b>Presentation #<\/b>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">3788eP<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <b>Abstract online<\/b>\n          <\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Monday, 19 October 2026 at 00:05 CEST (ESMO website)<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <br \/>The full abstract will be published on the ESMO Congress 2026 website on Monday, 19 October 2026. The presentation will subsequently be made available on Immutep\u2019s website.<\/p>\n<p align=\"justify\">\n        <b>About Immutep<\/b><br \/>\n        <br \/>Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3\u2019s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WIE2EUjk8VUz8rMi5im6XKtaxJgMtBrt18pckdRc3qnBvAfB2sJq9sNVWKcJarZG_OlD8ER8M4hkJ7_pA6_tyfZukFGEjTNjIUpr1g9uguM=\" rel=\"nofollow\" target=\"_blank\">www.immutep.com<\/a>.<\/p>\n<p align=\"justify\">\n        <b>Forward-Looking Statements<\/b>\u00a0<br \/>This press release\u00a0contains\u00a0forward-looking statements, including statements\u00a0regarding\u00a0anticipated clinical development, regulatory\u00a0progress\u00a0and potential benefits of\u00a0eftilagimod\u00a0alfa. These forward-looking statements are based on current expectations, estimates and projections, and involve known and unknown risks, uncertainties and other\u00a0important factors\u00a0that could cause actual results to differ materially from those expressed or implied in such statements.\u00a0<\/p>\n<p align=\"justify\">Factors that could cause actual results to differ materially include risks associated with clinical trial outcomes, regulatory developments, and the Company\u2019s ability to advance its product candidates.\u00a0<\/p>\n<p align=\"justify\">Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release. Immutep undertakes no obligation to update or revise such statements, except as required by applicable law.\u00a0<\/p>\n<p align=\"justify\">\n        <b>Disclaimer<\/b><br \/>\n        <br \/>This announcement has been prepared for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, securities in any\u00a0jurisdiction.<\/p>\n<p>\n        <b>Australian Investors\/Media:<\/b><br \/>\n        <br \/>Eleanor Pearson, Sodali &amp; Co.<br \/>+61 2 9066 4071;\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=frJHsN6quEBzdY2QM1GaBS7v0_SLoEFmviQ-rzS8Dh5bJnyO-VtZlj_FGBwQmcMrreL-9FkX_4XlOIggvw7xmcqM9fIPnFvysJpO8QBUGx93FVnZW_F4qpkqe_HH5nqI\" rel=\"nofollow\" target=\"_blank\">eleanor.pearson@sodali.com<\/a><\/p>\n<p>\n        <b>US Investors\/Media<\/b><br \/>\n        <br \/>Matthew Beck, astr partners <br \/>+1 (917) 415-1750; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kICsdhSs3Xg67olL09G75nzhUlfP6pjSV7Nt-TCaekKB8mG8aB_7eJrpgftyqMBogWaLHcklWw5w7G5cAgmtBf0Big6jyMuD9cp8J4UJNdtenKhJPSe7285n7coQHfve\" rel=\"nofollow\" target=\"_blank\">matthew.beck@astrpartners.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NzUzOCM3NzIxNDM2IzIwMTk4MzM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MGUwMWYyZGMtNjc4Yi00OGI3LWEyZmEtN2IwYThjY2UyOWQ3LTEwMzE0MDUtMjAyNi0wNy0yNC1lbg==\/tiny\/Immutep-Limited.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SYDNEY, AUSTRALIA, July 24, 2026 (GLOBE NEWSWIRE) &#8212; Immutep Limited (ASX: IMM; NASDAQ: IMMP) (\u201cImmutep\u201d or \u201cthe Company\u201d), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announced that an abstract for the investigator-initiated EFTISARC-NEO Phase II trial evaluating its first-in-class MHC Class II agonist, eftilagimod alfa (\u201cefti\u201d), has been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place 23\u201327 October 2026 in Madrid, Spain. The abstract reports health-related quality of life (HRQoL) data from EFTISARC-NEO. Details of the accepted abstract and poster are as follows: Title Health-related quality of life (HRQoL) during neoadjuvant treatment with eftilagimod alfa, pembrolizumab and radiotherapy in patients with soft tissue sarcoma (STS) \u2013 results from EFTISARC-NEO trial &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-984605","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SYDNEY, AUSTRALIA, July 24, 2026 (GLOBE NEWSWIRE) &#8212; Immutep Limited (ASX: IMM; NASDAQ: IMMP) (\u201cImmutep\u201d or \u201cthe Company\u201d), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announced that an abstract for the investigator-initiated EFTISARC-NEO Phase II trial evaluating its first-in-class MHC Class II agonist, eftilagimod alfa (\u201cefti\u201d), has been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place 23\u201327 October 2026 in Madrid, Spain. The abstract reports health-related quality of life (HRQoL) data from EFTISARC-NEO. Details of the accepted abstract and poster are as follows: Title Health-related quality of life (HRQoL) during neoadjuvant treatment with eftilagimod alfa, pembrolizumab and radiotherapy in patients with soft tissue sarcoma (STS) \u2013 results from EFTISARC-NEO trial &hellip; Continue reading &quot;Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-24T12:27:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NzUzOCM3NzIxNDM2IzIwMTk4MzM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026\",\"datePublished\":\"2026-07-24T12:27:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026\\\/\"},\"wordCount\":449,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2NzUzOCM3NzIxNDM2IzIwMTk4MzM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026\\\/\",\"name\":\"Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2NzUzOCM3NzIxNDM2IzIwMTk4MzM=\",\"datePublished\":\"2026-07-24T12:27:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2NzUzOCM3NzIxNDM2IzIwMTk4MzM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2NzUzOCM3NzIxNDM2IzIwMTk4MzM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026\/","og_locale":"en_US","og_type":"article","og_title":"Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026 - Market Newsdesk","og_description":"SYDNEY, AUSTRALIA, July 24, 2026 (GLOBE NEWSWIRE) &#8212; Immutep Limited (ASX: IMM; NASDAQ: IMMP) (\u201cImmutep\u201d or \u201cthe Company\u201d), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announced that an abstract for the investigator-initiated EFTISARC-NEO Phase II trial evaluating its first-in-class MHC Class II agonist, eftilagimod alfa (\u201cefti\u201d), has been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place 23\u201327 October 2026 in Madrid, Spain. The abstract reports health-related quality of life (HRQoL) data from EFTISARC-NEO. Details of the accepted abstract and poster are as follows: Title Health-related quality of life (HRQoL) during neoadjuvant treatment with eftilagimod alfa, pembrolizumab and radiotherapy in patients with soft tissue sarcoma (STS) \u2013 results from EFTISARC-NEO trial &hellip; Continue reading \"Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-24T12:27:02+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NzUzOCM3NzIxNDM2IzIwMTk4MzM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026","datePublished":"2026-07-24T12:27:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026\/"},"wordCount":449,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NzUzOCM3NzIxNDM2IzIwMTk4MzM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026\/","name":"Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NzUzOCM3NzIxNDM2IzIwMTk4MzM=","datePublished":"2026-07-24T12:27:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NzUzOCM3NzIxNDM2IzIwMTk4MzM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NzUzOCM3NzIxNDM2IzIwMTk4MzM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/984605","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=984605"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/984605\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=984605"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=984605"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=984605"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}